title: Subjective perception of cognition is related to mood and not performance.
abstract: OBJECTIVE
  Clinicians monitor cognitive effects of drugs primarily by asking patients to describe their side effects. We examined the relationship of subjective perception of cognition to mood and objective cognitive performance in healthy volunteers and neurological patients.
  
  
  METHODS
  Three separate experiments used healthy adults treated with lamotrigine (LTG) and topiramate (TPM), adults with epilepsy on LTG or TPM, and patients with idiopathic Parkinson's disease. Correlations were calculated for change scores on and off drugs in the first two experiments and for the single assessment in Experiment 3.
  
  
  RESULTS
  Across all three experiments, significant correlations were more frequent (chi(2)=259, P < or = 0.000) for mood versus subjective cognitive perception (59%) compared with subjective versus objective cognition (2%) and mood versus objective cognitive performance (2%).
  
  
  CONCLUSIONS
  Subjective perception of cognitive effects is related more to mood than objective performance. Clinicians should be aware of this relationship when assessing patients' cognitive complaints.
authors.affiliation: Experimental and Clinical Pharmacology, University of Minnesota, 717 Delaware Street SE, Room 517, Minneapolis, MN 55414, USA. marin007@umn.edu
authors.forename: S E
authors.initials: SE
authors.lastname: Marino
authors.forename: K J
authors.initials: KJ
authors.lastname: Meador
authors.forename: D W
authors.initials: DW
authors.lastname: Loring
authors.forename: M S
authors.initials: MS
authors.lastname: Okun
authors.forename: H H
authors.initials: HH
authors.lastname: Fernandez
authors.forename: A J
authors.initials: AJ
authors.lastname: Fessler
authors.forename: R P
authors.initials: RP
authors.lastname: Kustra
authors.forename: J M
authors.initials: JM
authors.lastname: Miller
authors.forename: P G
authors.initials: PG
authors.lastname: Ray
authors.forename: A
authors.initials: A
authors.lastname: Roy
authors.forename: M R
authors.initials: MR
authors.lastname: Schoenberg
authors.forename: V J
authors.initials: VJ
authors.lastname: Vahle
authors.forename: M A
authors.initials: MA
authors.lastname: Werz
mesh_terms: D000328:Adult; D000339:Affect / Q000187:drug effects / Q000502:physiology*; D000927:Anticonvulsants / Q000494:pharmacology* / Q000627:therapeutic use; D003071:Cognition / Q000187:drug effects / Q000502:physiology*; D018592:Cross-Over Studies; D003863:Depression / Q000523:psychology; D004311:Double-Blind Method; D004828:Epilepsies, Partial / Q000188:drug therapy / Q000523:psychology*; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D000077213:Lamotrigine; D008297:Male; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000188:drug therapy / Q000523:psychology*; D011597:Psychomotor Performance / Q000187:drug effects / Q000502:physiology*; D011788:Quality of Life; D012649:Self Concept; D000077236:Topiramate; D014227:Triazines / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000927:Anticonvulsants; D014227:Triazines; D000077236:Topiramate; D005632:Fructose; D000077213:Lamotrigine